The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma
Author Information
Author(s): Koumpis Epameinondas, Georgoulis Vasileios, Papathanasiou Konstantina, Papoudou-Bai Alexandra, Kanavaros Panagiotis, Kolettas Evangelos, Hatzimichael Eleftheria
Primary Institution: University of Ioannina
Hypothesis
This review examines the role of miR-155 in DLBCL and its potential as a future diagnostic, prognostic, or predictive biomarker.
Conclusion
MiR-155 is a significant oncomiR in DLBCL and holds potential as a diagnostic, prognostic, and predictive biomarker.
Supporting Evidence
- MiR-155 is involved in the pathophysiology of DLBCL and regulates key pathways and immune responses.
- High levels of miR-155 have been associated with poorer survival in some studies.
- MiR-155 can be detected in both tumor tissue and peripheral blood, making it a potential non-invasive biomarker.
- Conflicting results exist regarding the diagnostic and prognostic value of miR-155 in DLBCL.
Takeaway
MiR-155 is a tiny molecule that helps doctors understand and predict how aggressive a type of blood cancer called DLBCL might be.
Methodology
This is a narrative review based on bibliographic surveys using databases like PubMed and Google Scholar.
Limitations
The study is limited by a non-systematic search of the literature and the lack of standardized protocols for miRNA measurement.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website